Cargando…
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumo...
Autores principales: | Dagar, Gunjan, Gupta, Ashna, Masoodi, Tariq, Nisar, Sabah, Merhi, Maysaloun, Hashem, Sheema, Chauhan, Ravi, Dagar, Manisha, Mirza, Sameer, Bagga, Puneet, Kumar, Rakesh, Akil, Ammira S. Al-Shabeeb, Macha, Muzafar A., Haris, Mohammad, Uddin, Shahab, Singh, Mayank, Bhat, Ajaz A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327392/ https://www.ncbi.nlm.nih.gov/pubmed/37420216 http://dx.doi.org/10.1186/s12967-023-04292-3 |
Ejemplares similares
-
Correction: Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
por: Dagar, Gunjan, et al.
Publicado: (2023) -
Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics
por: Bhat, Ajaz A., et al.
Publicado: (2022) -
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
por: Sadida, Hana Q., et al.
Publicado: (2023) -
Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer
por: Nisar, Sabah, et al.
Publicado: (2020) -
Ubiquitin specific peptidase 37 and PCNA interaction promotes osteosarcoma pathogenesis by modulating replication fork progression
por: Chauhan, Ravi, et al.
Publicado: (2023)